Dongzheng Gai

Role not yet determined Is this you? Add your title

UAMS

8 h-index 26 pubs 258 cited

Research Areas

Biomedical Subjects

Links

Lab Website

OverviewAI-generated summary

Dongzheng Gai's research focuses on understanding disease mechanisms, particularly in the context of cancer and bone biology. His work investigates how specific genes and cellular processes contribute to tumor development and progression, with a recent emphasis on multiple myeloma and B cell malignancies. Gai has published on the role of TRIP13 in accelerating tumor development and the impact of NEK2 expression on T cell immunity in multiple myeloma. He has also explored the regulation of osteoclastogenesis and bone resorption by GPR109A and CST6, contributing to the understanding of osteolytic bone disease in multiple myeloma. Additionally, Gai has investigated biomarkers for lung cancer diagnosis and gene signatures for predicting the progression of MGUS to multiple myeloma. His research has involved animal models, including mice, to study these biological processes.

Metrics

h-index: 8
Publications: 26
Citations: 258

Selected Publications

Cystatin M/E Ameliorates Multiple Myeloma-Induced Hyper Osteolytic Bone Resorption (2025)

Cancers 1 citation DOI OpenAlex
Cystatin M/E ameliorates bone resorption through increasing osteoclastic cell estrogen influx (2024)

Research Square 1 citation DOI OpenAlex
Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth (2024)

Nature Communications 47 citations DOI OpenAlex
BCMA- and CST6-specific CAR T cells lyse multiple myeloma cells and suppress murine osteolytic lesions (2023)

Journal of Clinical Investigation 7 citations DOI OpenAlex
High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma (2023)

Cell Reports Medicine 17 citations DOI OpenAlex
P-066 BCMA-CAR-T cells with synthetic circuits of CST6 lyse tumor cells and suppress osteolytic lesions in multiple myeloma (2023)

Clinical Lymphoma Myeloma & Leukemia DOI OpenAlex
A gene signature can predict risk of MGUS progressing to multiple myeloma (2023)

Journal of Hematology & Oncology 15 citations DOI OpenAlex
Decreased bone resorption in Ezh2 myeloid cell conditional knockout mouse model (2023)

The FASEB Journal 12 citations DOI OpenAlex
A Gene Signature Can Predict Risk of MGUS Progressing to Multiple Myeloma (2023)

SSRN Electronic Journal DOI OpenAlex
A 12 Gene Signature Accurately Predicts Multiple Myeloma Progression from Monoclonal Gammopathy of Undetermined Significance (2022)

Blood DOI OpenAlex
CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation (2022)

Journal of Clinical Investigation 25 citations DOI OpenAlex
Deep-Sequencing Can be Used to Reconstruct and Extend Microarray-Based Classification and Risk Stratification for Multiple Myeloma (2021)

OpenAlex
NEK2 Inhibition Enhances the Efficacy of PD-1/PD-L1 Blockade in Multiple Myeloma (2021)

Blood 3 citations DOI OpenAlex
Ezh2 mediates epigenetic regulation of osteoclastogenesis and bone remodeling in mice (2021)

bioRxiv (Cold Spring Harbor Laboratory) 1 citation DOI OpenAlex
GPR109A mediates the effects of hippuric acid on regulating osteoclastogenesis and bone resorption in mice (2021)

Communications Biology 32 citations DOI OpenAlex